Literature DB >> 22003265

UTILIZTION OF THE SUZUKI COUPLING TO ENHANCE THE ANTITUBERCULOSIS ACTIVITY OF ARYL OXAZOLES.

Garrett C Moraski1, Scott G Franzblau, Marvin J Miller.   

Abstract

Potent antituberculosis aryl oxazoles can be made in an efficient three step process--formation of β-hydroxy amides with serine benzyl ester; cyclization to afford oxazolines; and then dehydration to give the corresponding oxazoles. Furthermore, incorporation of an appropriate aryl halide allows utilization of the Suzuki cross coupling reaction to access new chemical space and more elaborate analogs. The compounds prepared by this method were shown to possess improved activity against M. tuberculosis, extremely low toxicity toward VERO cells and, as a result, high therapeutic indexes.

Entities:  

Year:  2010        PMID: 22003265      PMCID: PMC3192507          DOI: 10.3987/COM-09-S(S)69

Source DB:  PubMed          Journal:  Heterocycles        ISSN: 0385-5414            Impact factor:   0.831


  11 in total

1.  Improved green fluorescent protein reporter gene-based microplate screening for antituberculosis compounds by utilizing an acetamidase promoter.

Authors:  Chartchai Changsen; Scott G Franzblau; Prasit Palittapongarnpim
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

2.  WHO policies for tuberculosis control.

Authors:  Dermot Maher; Léopold Blanc; Mario Raviglione
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

3.  Synthesis and studies of catechol-containing mycobactin S and T analogs.

Authors:  Andrew J Walz; Ute Möllmann; Marvin J Miller
Journal:  Org Biomol Chem       Date:  2007-04-19       Impact factor: 3.876

Review 4.  Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis.

Authors:  James C Sacchettini; Eric J Rubin; Joel S Freundlich
Journal:  Nat Rev Microbiol       Date:  2008-01       Impact factor: 60.633

5.  Vero cell assay validation of an alternative to the Ph. Eur. diphtheria potency tests.

Authors:  A M Gommer
Journal:  Dev Biol Stand       Date:  1996

6.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.

Authors:  C K Stover; P Warrener; D R VanDevanter; D R Sherman; T M Arain; M H Langhorne; S W Anderson; J A Towell; Y Yuan; D N McMurray; B N Kreiswirth; C E Barry; W R Baker
Journal:  Nature       Date:  2000-06-22       Impact factor: 49.962

7.  Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.

Authors:  Sang Hyun Cho; Saradee Warit; Baojie Wan; Chang Hwa Hwang; Guido F Pauli; Scott G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

8.  Synthesis of functionalized oxazolines and oxazoles with DAST and Deoxo-Fluor.

Authors:  A J Phillips; Y Uto; P Wipf; M J Reno; D R Williams
Journal:  Org Lett       Date:  2000-04-20       Impact factor: 6.005

9.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.

Authors:  L Collins; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 10.  Utilization of microbial iron assimilation processes for the development of new antibiotics and inspiration for the design of new anticancer agents.

Authors:  Marvin J Miller; Helen Zhu; Yanping Xu; Chunrui Wu; Andrew J Walz; Anne Vergne; John M Roosenberg; Garrett Moraski; Albert A Minnick; Julia McKee-Dolence; Jingdan Hu; Kelley Fennell; E Kurt Dolence; Li Dong; Scott Franzblau; Francois Malouin; Ute Möllmann
Journal:  Biometals       Date:  2009-01-07       Impact factor: 2.949

View more
  3 in total

1.  N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide as a new scaffold that provides rapid access to antimicrotubule agents: synthesis and evaluation of antiproliferative activity against select cancer cell lines.

Authors:  Jonathan A Stefely; Rahul Palchaudhuri; Patricia A Miller; Rebecca J Peterson; Garrett C Moraski; Paul J Hergenrother; Marvin J Miller
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

2.  Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.

Authors:  Garrett C Moraski; Lowell D Markley; Mayland Chang; Sanghyun Cho; Scott G Franzblau; Chang Hwa Hwang; Helena Boshoff; Marvin J Miller
Journal:  Bioorg Med Chem       Date:  2012-02-16       Impact factor: 3.641

3.  Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity.

Authors:  Garrett C Moraski; Lowell D Markley; Philip A Hipskind; Helena Boshoff; Sanghyun Cho; Scott G Franzblau; Marvin J Miller
Journal:  ACS Med Chem Lett       Date:  2011-06-09       Impact factor: 4.345

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.